Steam Is Out. Vaporized Hydrogen Peroxide Is In.

Europe's VHP sterilisation market is forecast to grow from EUR 520M to EUR 920M by 2035 as pharma growth and EU rules drive adoption

20 May 2026

A technology that breaks down into water and oxygen after each use has an obvious pitch. Vaporised hydrogen peroxide, long a specialist solution for sensitive environments, is now moving into the mainstream of European healthcare and pharmaceutical manufacturing. Analysts put the European market at between EUR 450 million and EUR 520 million this year. By 2035, that range climbs to EUR 780 million to EUR 920 million.

Three forces are converging. Regulatory pressure from EU MDR and GMP Annex 1 requirements is tightening validation standards across the continent. Pharmaceutical output, particularly in biologics, cell therapy, and gene therapy, is growing fastest in Germany, France, the UK, and Switzerland, which together account for more than 55 percent of European adoption. And aging hospital equipment is entering replacement cycles, pulling demand forward.

Steam cannot serve this market. Heat-sensitive advanced therapies require low-temperature validated processes, and ethylene oxide faces narrowing occupational safety limits under EU rules. VHP sidesteps both problems. Its residue profile, breaking down to harmless compounds, satisfies occupational health directives and hospital sustainability targets at once. That dual compliance is not incidental; for procurement officers weighing recurring costs against audit risk, it matters.

Installation figures reflect this. Between 1,800 and 2,200 new VHP systems are expected across European facilities in 2026. By 2035, annual installations should reach 3,000 to 3,800. Portable and mobile units are growing fastest, at 8 to 10 percent per year, as ambulatory surgical centres and smaller clinics seek validated capacity without committing to permanent infrastructure.

Cost pressures remain. Consumables and cycle monitoring add recurring expense, a strain for public hospitals on fixed procurement budgets. Globally, VHP revenues are forecast to rise from USD 1.58 billion in 2026 to USD 3.4 billion by 2035. The tightening of European validation rules has reframed the calculation. What was once a backup option is becoming a baseline requirement.